|Company name||CareDX, Inc.|
NEW YORK, August 5, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against CareDx, Inc. (NYSE: CDNA) on behalf of CareDX stockholders. Our investigation concerns whether CareDX has violated the federal securities laws and/or engaged in other unlawful business practices.
On July 16, 2019, Kerrisdale Capital Research released a report alleging, among other things, that the Company’s diagnostic test, AlloSure, is “fundamentally incapable of identifying the most common type of kidney rejection.” Moreover, the report stated that AlloSure revenues are derived from “protocol usage in clinical testing, which is suffering 20-30% quarterly attrition.”
On this news, shares of CareDx fell as much as 14%, from $37.40 per share to $32.57 per share, thereby injuring investors.
If you purchased or otherwise acquired CareDX shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.